Clinical trial NCT01862003: Phase I/II Trial of Antagonism of HER in GI Cancer
Official title: AZD8931, an Inhibitor of EGFR, ERBB2 and ERBB3 Signalling, in Combination With FOLFIRI: a Phase I/II Study to Determine the Importance of Schedule and Activity in Colorectal Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Metastatic Colorectal Cancer
Recurrent Colorectal Cancer
Keywords: Colorectal cancer
Metastatic Colorectal cancer
Recurrent Colorectal cancer
FOLFIRI
AZD8931
Chemotherapy
EGFR
Lead sponsor: University College, London
Sponsor class: OTHER
Collaborators: name: Cancer Research UK
name: AstraZeneca
name: National Institute for Health Research, United Kingdom
First posted: 2013-05-24
Enrollment: 24
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Recruitment to phase I of the PANTHER trial is complete.

Phase II, is to evaluate the best overall response rate for AZD8931 + FOLFIRI treatment.

Detailed description: PANTHER is a registered phase I/phase II trial in patients with recurrent or metastatic colorectal cancer.

The phase II part of the study will be a single arm trial. Patients will receive AZD8931 (an EGFR/ERBB inhibitor) in combination with FOLinic acid, Fluorouracil and IRInotecan (FOLFIRI), Treatment will be given in two-weekly cycles. Phase II's primary objective is to evaluate the Best overall response

Eligibility criteria: Inclusion Criteria:

1. Histopathological/cytological diagnosis of non-resectable, recurrent or metastatic colorectal cancer
2. Tumour with wild-type RAS
3. Measurable disease evaluated by RECIST criteria v1.1
4. WHO performance status 0 or 1
5. Age ≥ 16
6. Estimated life expectancy \> 3 months
7. Adequate haematological function:

   * Haemoglobin ≥100 g/L
   * Absolute neutrophil count ≥1.5 x 10\^9/L
   * Platelet count ≥100 x 10\^9/L
8. Adequate liver function:

   * Total bilirubin ≤1.5 x upper limit of normal (ULN) (except for patients with known documented cases of Gilbert's syndrome)
   * ALT, AST \& ALP ≤2.5 x ULN in the absence of noted liver metastases
   * ALT, AST \& ALP ≤5 x ULN in the presence of liver metastases
9. Adequate renal function:

   * Serum creatinine ≤1.5 x ULN
   * Calculated creatinine clearance ≥30 mL/min
10. Adequate biliary drainage (patients with stents are eligible)
11. Adequate venous access for collection of exploratory biological samples
12. Women of child-bearing potential must have a negative pregnancy test prior to study entry. Female patients and male patients with partners of child-bearing potential must agree to use an adequate contraception method, which must be continued for 6 months after completion of chemotherapy
13. Must be able to swallow AZD8931 tablets
14. Capable of giving written informed consent
15. The following prior therapy is allowed:

    * Surgery - patients may have undergone a non-curative operation or palliative bypass surgery only. Patients who have previously undergone curative surgery must have evidence of non-resectable disease relapse
    * Radiotherapy - for localised disease
    * Prior adjuvant chemotherapy - provided this was completed at least 6 months before trial entry

Exclusion Criteria:

1. Patients undergoing treatment with curative intent
2. Any prior treatment with agents targeting the ERBB pathway
3. Treatment with experimental drugs within 30 days or 5 half-lives of first dose of AZD8931
4. Previous palliative chemotherapy
5. Prior treatment with anthracyclines or mitoxantrone
6. Current disease or condition known to interfere with absorption, distribution, metabolism or excretion of drugs (including refractory nausea and vomiting, chronic gastrointestinal disease (e.g. inflammatory bowel disease), or significant bowel resection)
7. History of prior malignancy that will interfere with the response evaluation (exceptions listed in protocol)
8. Evidence of severe/uncontrolled systemic diseases or laboratory finding that makes it undesirable for the patient to participate in the trial
9. Evidence of active uncontrolled infection
10. Patients with clinically significant ascites and/or effusions
11. Regular use of anti-diarrhoeal
12. Pregnant or lactating women
13. Cardiac conditions (as detailed in the trial protocol)
14. Any psychiatric or other disorder (e.g. brain metastases) likely to impact the ability to give informed consent
15. Eye conditions (as detailed in the trial protocol)
16. Patients with chronic skin conditions e.g. acne rosacea, psoriasis, severe atopic eczema
17. Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease
18. History or repeated unexplained episodes of syncope/dizziness
19. Known hypersensitivity to AZD8931, its excipients, or drugs in its class
20. The use of drugs/substances known to inhibit or induce CYP3A4 or CYP2D6, or those known to prolong QT interval, which cannot be discontinued for the duration of trial treatment
21. Patients with hereditary fructose intolerance

Primary outcomes:
measure: Best overall response
timeFrame: From registration to date of documented best response, assessed up to 36 months
Secondary outcomes:
measure: To evaluate the efficacy of AZD8931 plus FOLFIRI
timeFrame: Baseline to 12 weeks post treatment start
measure: Progression Free Survival
timeFrame: From date of randomisation to date of documented disease progression or death from any cause, whichever comes first, assessed up to 3 years from date of registration/ randomisation
measure: Overall Survival
timeFrame: From date of registration/ randomisation until date of death or date of last follow-up assessment (up to 3 years from date of registration/ randomisation)
measure: Occurrence and Severity of Adverse Events
timeFrame: From date of registration/ randomisation until 30 days after completion of trial treatment (AZD8931 and FOLFIRI)
Other outcomes:
Locations:
city: London
country: United Kingdom
facility: Barts Health NHS Trust
city: London
country: United Kingdom
facility: Guy's and St Thomas' NHS Foundation Trust
city: London
country: United Kingdom
facility: University College London Hospital NHS Foundation Trust
city: Manchester
country: United Kingdom
facility: The Christie NHS Foundation Trust
Study officials:
affiliation: University College London (UCL) Cancer Institute
name: Daniel Hochhauser, BA, MBBS, MRCP, D.PHIL, FRCP
role: PRINCIPAL_INVESTIGATOR
References:
citation: Propper DJ, Gao F, Saunders MP, Sarker D, Hartley JA, Spanswick VJ, Lowe HL, Hackett LD, Ng TT, Barber PR, Weitsman GE, Pearce S, White L, Lopes A, Forsyth S, Hochhauser D. PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer. Br J Cancer. 2023 Jan;128(2):245-254. doi: 10.1038/s41416-022-02015-x. Epub 2022 Nov 9.